Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 4
4 · RayzeBio, Inc. · Filed Sep 19, 2023
Insider Transaction Report
Form 4
RayzeBio, Inc.RYZB
Transactions
- Conversion
Common Stock
2023-09-19+1,557,846→ 1,557,846 total - Conversion
Series D Preferred Stock
2023-09-19−1,557,846→ 0 total→ Common Stock (1,557,846 underlying)
Footnotes (1)
- [F1]Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series D Preferred Stock had no expiration date.